18.52
+11.03(+147.26%)
Currency In USD
| Previous Close | 7.49 |
| Open | 12.83 |
| Day High | 19.54 |
| Day Low | 12.72 |
| 52-Week High | 19.54 |
| 52-Week Low | 5.28 |
| Volume | 143.9M |
| Average Volume | 2.6M |
| Market Cap | 3.04B |
| PE | -28.49 |
| EPS | -0.65 |
| Moving Average 50 Days | 7.49 |
| Moving Average 200 Days | 7.76 |
| Change | 11.03 |
If you invested $1000 in Wave Life Sciences Ltd. (WVE) 10 years ago, it would be worth $1,307.91 as of December 09, 2025 at a share price of $18.52. Whereas If you bought $1000 worth of Wave Life Sciences Ltd. (WVE) shares 5 years ago, it would be worth $2,150.99 as of December 09, 2025 at a share price of $18.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
GlobeNewswire Inc.
12 hours ago
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”),
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2%
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
GlobeNewswire Inc.
Dec 07, 2025 9:00 PM GMT
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from t